IP Library Assignment 043041/0880
Patent Assignment
Reel/Frame 043041/0880

Security Interest

Recorded: 2017-07-19 Pages: 11
Assignor
SALIX PHARMACEUTICALS, LTD
Executed: 2017-07-17
Assignee
THE BANK OF NEW YORK MELLON
101 BARCLAY STREET, FLOOR 7E, NEW YORK, NEW YORK, 10286
Covered Properties (42)
Formulations and Uses of 2-Hydroxy-5-Phenylazobenzoic Acid Derivatives
Patent: 8,921,344 →
Application: 11/592,854 →
Publication: US 2007/0167416
Formulations and Uses of 2-Hydroxy-5-Phenylazobenzoic Acid Derivatives
Patent: 7,452,872 →
Application: 11/835,897 →
Publication: US 2007/0265232
Formulations and Uses of 2-Hydroxy-5-Phenylazobenzoic Acid Derivatives
Patent: 7,625,884 →
Application: 11/877,589 →
Publication: US 2008/0096849
Colonic Purgative Composition with Soluble Binding Agent
Patent: 7,718,197 →
Application: 12/075,772 →
Publication: US 2008/0213393
Rifaximin Anti-Rectal Dysfunction Preparation
Patent: 8,987,292 →
Application: 12/224,774 →
Publication: US 2010/0048520
Compositions and Methods for the Treatment of Radiation Proctosigmoitis
Application: 12/309,893 →
Publication: US 2010/0069421
Forms of Rifaximin and Uses Thereof
Patent: 8,067,429 →
Application: 12/393,012 →
Publication: US 2010/0239664
Methods for Treating Diarrhea-Associated Irritable Bowel Syndrome
Patent: 8,309,569 →
Application: 12/393,979 →
Publication: US 2011/0118295
Forms of Rifaximin and Uses Thereof
Patent: 8,486,956 →
Application: 12/708,836 →
Publication: US 2010/0174064
Methods of Treating Travelers Diarrhea and Hepatic Encephalopathy
Patent: 7,928,115 →
Application: 12/957,831 →
Publication: US 2011/0065740
Methods of Treating Traveler's Diarrhea and Hepatic Encephalopathy
Patent: 8,829,017 →
Application: 13/076,967 →
Publication: US 2011/0178113
Formulations and Uses of 2-Hydroxy-5-Phenylazobenzoic Acid Derivatives for the Treatment of Males
Patent: 8,497,256 →
Application: 13/094,261 →
Publication: US 2012/0058184
Forms of Rifaximin and Uses Thereof
Patent: 8,513,275 →
Application: 13/152,804 →
Publication: US 2012/0108620
Forms of Rifaximin and Uses Thereof
Patent: 8,735,419 →
Application: 13/371,238 →
Publication: US 2012/0207833
Forms of Rifaximin and Uses Thereof
Patent: 8,227,482 →
Application: 13/434,766 →
Publication: US 2012/0207832
Forms of Rifaximin and Uses Thereof
Patent: 8,507,517 →
Application: 13/530,386 →
Publication: US 2012/0264774
Forms of Rifaximin and Uses Thereof
Patent: 8,569,326 →
Application: 13/587,537 →
Publication: US 2012/0316334
Methods for Treating Infection
Application: 13/587,539 →
Publication: US 2013/0210852
Forms of Rifaximin and Uses Thereof
Patent: 8,754,098 →
Application: 13/593,453 →
Publication: US 2013/0066079
Forms of Rifaximin and Uses Thereof
Patent: 9,181,274 →
Application: 13/644,241 →
Publication: US 2014/0011828
Methods of Treating Traveler's Diarrhea and Hepatic Encephalopathy
Patent: 8,946,252 →
Application: 13/654,978 →
Publication: US 2013/0059875
Methods for Treating Irritable Bowel Syndrome (Ibs) and Infections
Application: 13/667,585 →
Publication: US 2013/0184302
Methods for Treatment and Prevention of Opioid Induced Constipation Using Oral Compositions of Methylnaltrexone
Application: 13/720,235 →
Publication: US 2013/0317050
Methods of Treating Hepatic Encephalopathy
Patent: 8,642,573 →
Application: 13/737,535 →
Publication: US 2013/0123209
Methods for Treating Irritable Bowel Syndrome (Ibs)
Patent: 9,566,270 →
Application: 13/755,578 →
Publication: US 2013/0203795
Methods of Treating Hepatic Encephalopathy
Patent: 8,969,398 →
Application: 13/768,617 →
Publication: US 2013/0171090
Methods of Treating Hepatic Encephalopathy
Patent: 9,421,195 →
Application: 13/914,074 →
Publication: US 2013/0345166
Forms of Rifaximin and Uses Thereof
Patent: 9,034,892 →
Application: 13/929,003 →
Publication: US 2014/0141081
New Forms of Rifaximin and Uses Thereof
Patent: 8,815,888 →
Application: 13/955,660 →
Publication: US 2013/0317225
Forms of Rifaximin and Uses Thereof
Patent: 9,273,066 →
Application: 14/062,333 →
Publication: US 2014/0179916
Formulations of Rifaximin and Uses Thereof
Patent: 9,737,610 →
Application: 14/250,293 →
Publication: US 2015/0133482
Forms of Rifaximin and Uses Thereof
Patent: 9,133,217 →
Application: 14/288,184 →
Publication: US 2015/0118307
Forms of Rifaximin and Uses Thereof
Patent: 9,359,357 →
Application: 14/580,458 →
Publication: US 2015/0299199
Methods of Treating Traveler's Diarrhea and Hepatic Encephalopathy
Patent: 9,629,828 →
Application: 14/605,109 →
Publication: US 2015/0141450
Methods of Treating Hepatic Encephalopathy
Patent: 9,629,829 →
Application: 14/612,697 →
Publication: US 2015/0157612
Prevention, Treatment, and Amelioration of Radiation Induced Enteritis
Application: 14/731,692 →
Publication: US 2016/0120886
Methods for Treating Bowel Diseases
Application: 14/799,018 →
Publication: US 2016/0000765
Forms of Rifaximin and Uses Thereof
Patent: 9,546,183 →
Application: 14/995,791 →
Publication: US 2016/0200738
Forms of Rifaximin and Uses Thereof
Patent: 9,700,545 →
Application: 15/141,099 →
Publication: US 2016/0317507
Methods of Treating Hepatic Encephalopathy
Patent: 9,855,254 →
Application: 15/212,720 →
Publication: US 2017/0042864
Formulations of Rifaximin and Uses Thereof
Application: 15/281,543 →
Publication: US 2017/0087134
Solid Dispersion Forms of Rifaximin
Application: 62/402,119 →
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Dec 11, 2014
From: GUSHURST, KAREN S.; YANG, DONGLAI; VLAHOVA, PETINKA; STULTS, JEFFREY S.
To: SALIX PHARMACEUTICALS, INC.
Reel/Frame 034477/0647 →
Assignment of Assignor's Interest Aug 11, 2016
From: GUSHURST, KAREN S.; YANG, DONGLAI; ROE, MELANIE; SCHULTHEISS, NATHAN
To: APTUIT, INC.
Reel/Frame 039653/0847 →
Assignment of Assignor's Interest Aug 19, 2016
From: APTUIT, INC.
To: SALIX PHARMACEUTICALS, LTD.
Reel/Frame 039763/0541 →
Assignment of Assignor's Interest Sep 25, 2017
From: PARENT, STEPHAN D.; MCQUEEN, LISA LYNN; ANDRES, PATRICIA; SCHIELDS, PAUL
To: SALIX PHARMACEUTICALS, LTD
Reel/Frame 043684/0269 →
Assignment of Assignor's Interest Sep 25, 2017
From: APTUIT, INC.
To: SALIX PHARMACEUTICALS, LTD
Reel/Frame 043684/0383 →
Corrective Assignment to Correct the Assignee Previously Recorded at Reel: 043684 Frame: 0269. Assignor(S) Hereby Confirms the Assignment. Oct 13, 2017
From: PARENT, STEPHAN D.; MCQUEEN, LISA LYNN; ANDRES, PATRICIA; SCHIELDS, PAUL
To: APTUIT, INC.
Reel/Frame 044280/0962 →
Security Interest Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
Security Interest Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
Security Interest Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
Assignment of Assignor's Interest Apr 22, 2019
From: SALIX PHARMACEUTICALS, LTD.
To: SALIX PHARMACEUTICALS, INC.
Reel/Frame 048953/0153 →
Assignment of Assignor's Interest May 6, 2019
From: SALIX PHARMACEUTICALS, LTD.
To: SALIX PHARMACEUTICALS, INC.
Reel/Frame 049090/0053 →
Assignment of Assignor's Interest May 13, 2019
From: SALIX PHARMACEUTICALS, LTD.
To: SALIX PHARMACEUTICALS, INC.
Reel/Frame 049157/0940 →
Assignment of Assignor's Interest Jun 12, 2019
From: SALIX PHARMACEUTICALS, LTD.
To: SALIX PHARMACEUTICALS, INC.
Reel/Frame 049444/0911 →
Assignment of Assignor's Interest Jun 25, 2019
From: SALIX PHARMACEUTICALS, LTD.
To: SALIX PHARMACEUTICALS, INC.
Reel/Frame 049579/0675 →
Assignment of Assignor's Interest Jun 25, 2019
From: SALIX PHARMACEUTICALS, LTD.
To: SALIX PHARMACEUTICALS, INC.
Reel/Frame 049578/0095 →
Security Interest Jun 8, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056811/0814 →
Security Agreement Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
Security Agreement (First Lien) Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
Security Agreement (Second Lien) Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
Release of Security Interest Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.
Reel/Frame 070778/0199 →
U.S. Patent Security Agreement Jun 13, 2025
From: MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; BAUSCH HEALTH US, LLC (F/K/A VALEANT PHARMACEUTICALS NORTH AMERICA LLC); PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 071564/0463 →
U.S. Patent Security Agreement Jun 13, 2025
From: MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; BAUSCH HEALTH US, LLC (F/K/A VALEANT PHARMACEUTICALS NORTH AMERICA LLC); PRECISION DERMATOLOGY, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 071566/0200 →
Release of Security Interest Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC
Reel/Frame 073637/0001 →
Release of Security Interest Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION
Reel/Frame 073654/0242 →
Release of Security Interest Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.
Reel/Frame 073637/0126 →